{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:24:23Z","timestamp":1707524663304},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,26]]},"DOI":"10.7759\/cureus.28429","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T13:02:39Z","timestamp":1661518959000},"source":"Crossref","is-referenced-by-count":0,"title":["Chronic Proton-Pump Inhibitor Therapy and Fracture Risk in Women Aged Between 50 and 65 years: A Retrospective Case-Control Study"],"prefix":"10.7759","author":[{"given":"Nimesh","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Fayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyansh","family":"Faldu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wissam","family":"Maroun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janki","family":"Chandarana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/1756284818777943","article-title":"Proton-pump inhibitors among adults: a nationwide drug-utilization study","volume":"11","author":"H\u00e1lfd\u00e1narson \u00d3\u00d6","year":"2018","unstructured":"H\u00e1lfd\u00e1narson \u00d3\u00d6, Potteg\u00e5rd A, Bj\u00f6rnsson ES, et al.. Proton-pump inhibitors among adults: a nationwide drug-utilization study. Therap Adv Gastroenterol. 2018, 11:1756284818777943. 10.1177\/1756284818777943","journal-title":"Therap Adv Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2020.09.015","article-title":"National trends in prescription proton pump inhibitor use and expenditure in the United States in 2002-2017 [PREPRINT]","author":"Mishuk AU","year":"2020","unstructured":"Mishuk AU, Chen L, Gaillard P, Westrick S, Hansen RA, Qian J. National trends in prescription proton pump inhibitor use and expenditure in the United States in 2002-2017 [PREPRINT]. J Am Pharm Assoc (2003). 2020, 10.1016\/j.japh.2020.09.015","journal-title":"J Am Pharm Assoc (2003)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4135","article-title":"Long-term use of proton pump inhibitors and prevalence of disease- and drug-related reasons for gastroprotection: a cross-sectional population-based study","volume":"26","author":"Wallerstedt SM","year":"2017","unstructured":"Wallerstedt SM, Fastbom J, Linke J, Vitols S. Long-term use of proton pump inhibitors and prevalence of disease- and drug-related reasons for gastroprotection: a cross-sectional population-based study. Pharmacoepidemiol Drug Saf. 2017, 26:9-16. 10.1002\/pds.4135","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.gassur.2006.07.010","article-title":"Prospective trial of laparoscopic Nissen fundoplication versus proton pump inhibitor therapy for gastroesophageal reflux disease: seven-year follow-up","volume":"10","author":"Mehta S","year":"2006","unstructured":"Mehta S, Bennett J, Mahon D, Rhodes M. Prospective trial of laparoscopic Nissen fundoplication versus proton pump inhibitor therapy for gastroesophageal reflux disease: seven-year follow-up. J Gastrointest Surg. 2006, 10:1312-7. 10.1016\/j.gassur.2006.07.010","journal-title":"J Gastrointest Surg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0b013e32833ea9d9","article-title":"Adverse effects of proton pump inhibitor drugs: clues and conclusions","volume":"26","author":"McCarthy DM","year":"2010","unstructured":"McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol. 2010, 26:624-31. 10.1097\/MOG.0b013e32833ea9d9","journal-title":"Curr Opin Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/0885066613516574","article-title":"Off-label use of gastrointestinal medications in the intensive care unit","volume":"30","author":"Barletta JF","year":"2015","unstructured":"Barletta JF, Lat I, Micek ST, Cohen H, Olsen KM, Haas CE. Off-label use of gastrointestinal medications in the intensive care unit. J Intensive Care Med. 2015, 30:217-25. 10.1177\/0885066613516574","journal-title":"J Intensive Care Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Yang YX","year":"2006","unstructured":"Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006, 296:2947-53. 10.1001\/jama.296.24.2947","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-012-2112-9","article-title":"The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study","volume":"24","author":"Fraser LA","year":"2013","unstructured":"Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013, 24:1161-8. 10.1007\/s00198-012-2112-9","journal-title":"Osteoporos Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2015.08.024","article-title":"The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: a prospective cohort study","volume":"81","author":"van der Hoorn MM","year":"2015","unstructured":"van der Hoorn MM, Tett SE, de Vries OJ, Dobson AJ, Peeters GM. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: a prospective cohort study. Bone. 2015, 81:675-82. 10.1016\/j.bone.2015.08.024","journal-title":"Bone"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.03.055","article-title":"Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients","volume":"139","author":"Corley DA","year":"2010","unstructured":"Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010, 139:93-101. 10.1053\/j.gastro.2010.03.055","journal-title":"Gastroenterology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-010-1337-8","article-title":"Use of proton pump inhibitors and risk of hip\/femur fracture: a population-based case-control study","volume":"22","author":"Pouwels S","year":"2011","unstructured":"Pouwels S, Lalmohamed A, Souverein P, et al.. Use of proton pump inhibitors and risk of hip\/femur fracture: a population-based case-control study. Osteoporos Int. 2011, 22:903-10. 10.1007\/s00198-010-1337-8","journal-title":"Osteoporos Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2012.09.028","article-title":"Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region","volume":"52","author":"Reyes C","year":"2013","unstructured":"Reyes C, Formiga F, Coderch M, et al.. Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region. Bone. 2013, 52:557-61. 10.1016\/j.bone.2012.09.028","journal-title":"Bone"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-016-0679-0","article-title":"Association of proton pump inhibitor use with recurrent falls and risk of fractures in older women: a study of medication use in older fallers","volume":"20","author":"Thaler HW","year":"2016","unstructured":"Thaler HW, Sterke CS, van der Cammen TJ. Association of proton pump inhibitor use with recurrent falls and risk of fractures in older women: a study of medication use in older fallers. J Nutr Health Aging. 2016, 20:77-81. 10.1007\/s12603-016-0679-0","journal-title":"J Nutr Health Aging"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-006-0021-7","article-title":"Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture","volume":"79","author":"Vestergaard P","year":"2006","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006, 79:76-83. 10.1007\/s00223-006-0021-7","journal-title":"Calcif Tissue Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-015-0699-6","article-title":"Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors","volume":"34","author":"Bahtiri E","year":"2016","unstructured":"Bahtiri E, Islami H, Hoxha R, et al.. Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors. J Bone Miner Metab. 2016, 34:571-9. 10.1007\/s00774-015-0699-6","journal-title":"J Bone Miner Metab"},{"key":"ref16","article-title":"Effect of long-term proton pump inhibitors on bone mineral density","volume":"96","author":"Romdhane H","year":"2018","unstructured":"Romdhane H, Ayadi S, Elleuch N, Abdelghani K. Effect of long-term proton pump inhibitors on bone mineral density. Tunis Med. 2018, 96:193-7.","journal-title":"Tunis Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12866","article-title":"Proton pump inhibitors use and change in bone mineral density","volume":"19","author":"Arj A","year":"2016","unstructured":"Arj A, Razavi Zade M, Yavari M, Akbari H, Zamani B, Asemi Z. Proton pump inhibitors use and change in bone mineral density. Int J Rheum Dis. 2016, 19:864-8. 10.1111\/1756-185X.12866","journal-title":"Int J Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16091571","article-title":"Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved","volume":"16","author":"Thong BK","year":"2019","unstructured":"Thong BK, Ima-Nirwana S, Chin KY. Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved. Int J Environ Res Public Health. 2019, 16:1571. 10.3390\/ijerph16091571","journal-title":"Int J Environ Res Public Health"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2014.05.019","article-title":"Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study","volume":"78","author":"Moberg LM","year":"2014","unstructured":"Moberg LM, Nilsson PM, Samsioe G, Borgfeldt C. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study. Maturitas. 2014, 78:310-5. 10.1016\/j.maturitas.2014.05.019","journal-title":"Maturitas"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.94","article-title":"Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative","volume":"170","author":"Gray SL","year":"2010","unstructured":"Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med. 2010, 170:765-71. 10.1001\/archinternmed.2010.94","journal-title":"Arch Intern Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.8.951","article-title":"Proton pump inhibitor use and risk of hip fractures in patients without major risk factors","volume":"28","author":"Kaye JA","year":"2008","unstructured":"Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008, 28:951-9. 10.1592\/phco.28.8.951","journal-title":"Pharmacotherapy"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji P","year":"2012","unstructured":"Hadji P, Zanchetta JR, Russo L, et al.. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int. 2012, 23:2141-50. 10.1007\/s00198-011-1856-y","journal-title":"Osteoporos Int"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X49671","article-title":"The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis","volume":"21","author":"Genant HK","year":"2005","unstructured":"Genant HK, Halse J, Briney WG, Xie L, Glass EV, Krege JH. The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin. 2005, 21:1027-34. 10.1185\/030079905X49671","journal-title":"Curr Med Res Opin"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s11999-011-1780-7","article-title":"Gender differences in osteoporosis and fractures","volume":"469","author":"Cawthon PM","year":"2011","unstructured":"Cawthon PM. Gender differences in osteoporosis and fractures. Clin Orthop Relat Res. 2011, 469:1900-5. 10.1007\/s11999-011-1780-7","journal-title":"Clin Orthop Relat Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cdtm.2015.02.006","article-title":"Primary osteoporosis in postmenopausal women","volume":"1","author":"Ji MX","year":"2015","unstructured":"Ji MX, Yu Q. Primary osteoporosis in postmenopausal women. Chronic Dis Transl Med. 2015, 1:9-13. 10.1016\/j.cdtm.2015.02.006","journal-title":"Chronic Dis Transl Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-012-2074-y","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"24","author":"Kanis JA","year":"2013","unstructured":"Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013, 24:23-57. 10.1007\/s00198-012-2074-y","journal-title":"Osteoporos Int"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-008-0560-z","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"19","author":"Kanis JA","year":"2008","unstructured":"Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008, 19:399-428. 10.1007\/s00198-008-0560-z","journal-title":"Osteoporos Int"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.1.77","article-title":"Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures","volume":"160","author":"Nevitt MC","year":"2000","unstructured":"Nevitt MC, Thompson DE, Black DM, Rubin SR, Ensrud K, Yates AJ, Cummings SR. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Arch Intern Med. 2000, 160:77-85. 10.1001\/archinte.160.1.77","journal-title":"Arch Intern Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S344191","article-title":"Balloon kyphoplasty vs vertebroplasty: a systematic review of height restoration in osteoporotic vertebral compression fractures","volume":"15","author":"Patel N","year":"2022","unstructured":"Patel N, Jacobs D, John J, et al.. Balloon kyphoplasty vs vertebroplasty: a systematic review of height restoration in osteoporotic vertebral compression fractures. J Pain Res. 2022, 15:1233-45. 10.2147\/JPR.S344191","journal-title":"J Pain Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/110108-chronic-proton-pump-inhibitor-therapy-and-fracture-risk-in-women-aged-between-50-and-65-years-a-retrospective-case-control-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:48:48Z","timestamp":1707508128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/110108-chronic-proton-pump-inhibitor-therapy-and-fracture-risk-in-women-aged-between-50-and-65-years-a-retrospective-case-control-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.28429","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,26]]}}}